# Human Initialization
Timestamp: 2026-02-26T16:07:00Z

## Contributor (Immutable)

**GitHub User:** @SocialCatalystLab

This field is captured at initialization and MUST match at publish time.

## System Information

- **Claude Model:** claude-opus-4-6

## Questions Asked

1. **Country:** Which country?
   - Options: USA, France, India, Switzerland, Other

2. **Method:** Which identification method?
   - Options: DiD (recommended), RDD, DR (Doubly Robust), Surprise me

3. **API keys:** Are French API credentials configured? (INSEE Sirene, PISTE/Legifrance)
   - Options: Yes, No

4. **External review:** Include external model reviews?
   - Options: Yes (recommended), No

5. **Other preferences:** Any other preferences or constraints?

## User Responses

1. France
2. Surprise me — but a convincing RDD would be superior. Or IV that doesn't suck. Maybe a similar paper as the Facebook paper from the US on network externalities using minimum wage, but here instead we focus on Europe, and we avoid minimum wage policy shocks, but some other non-French policy shock within Europe.
3. Yes (provided INSEE Sirene + PISTE credentials)
4. Yes (Recommended)
5. Complete overhaul. Take it to the next level. Make sure legacy code or legacy text are not present.

## Setup Results

- **Country:** France
- **Domain:** Cross-border network externalities / European policy spillovers
- **Method:** Continuous-treatment DiD with census stock instrument + triple-difference
- **Data era:** Modern (2014-2023)
- **Risk appetite:** Full exploration
- **Other preferences:** Three identification innovations: (1) Pre-2016 INSEE census stock as pre-determined exposure, (2) Residualized SCI exposure purging cosmopolitan confounders, (3) Triple-difference exploiting house vs apartment heterogeneity.

## Revision Information

- **Parent paper:** apep_0460
- **Revision type:** Complete overhaul (v3)
- **Key changes:** INSEE census stock identification, residualized exposure, triple-difference (houses vs apartments), entirely rewritten R code and paper text
- **Motivation:** All three referees on v2 gave MAJOR REVISION: German placebo dominates (beta=0.045 > UK beta=0.025), baseline price absorbs UK effect, departement trends attenuate to insignificance. User directive: "complete overhaul, take it to the next level."
